The Sygnature leadership team encompasses a rich mix of backgrounds, experiences and skills. Passionate scientists, chemists, biochemists, biologists, computational chemists, and pharmacologists work together to make Sygnature the partner of choice, the expert provider of drug discovery services who will do everything to make your project succeed.
Filter by:
Dr Simon Hirst
Chief Executive Officer
Dr Paul Overton
Chief Commercial Officer
Dr Jonathan Williams
Chief Operating Officer
Louisa Jordison
Chief Financial Officer
Dr Stuart Onions
Senior VP, Alliance Management
Dr John Unitt
Vice President, Immunology and Inflammation Drug Discovery
Dr Geraint Jones
Director of Chemistry
Dr Iain Walters
Director of Chemistry
Colin Sambrook Smith
Director of Computational Sciences and Informatics
Dr Richard Weaver
Senior VP, Preclinical Development
Dr Allan Jordan
Vice President of Oncology Drug Discovery
Jane Kendrew
Director of Translational Oncology
Dr Stephen Young
VP Business Development
Anders Lindstrom
Director of Marketing
Mark Thomas
Senior Vice President of Human Resources
Who We Are
Sygnature Discovery prides itself on offering a unique, high-quality, distinctive and tailored integrated drug discovery service to our clients. Our mission is to be admired for the science we do,…
Working with Us
No two projects will ever be the same, but there are commonly recurring challenges that hinder progress towards a strong candidate molecule. Sygnature draws on the past experience of over…
Company History
Since 2004 Sygnature Discovery has been offering high-quality drug discovery services and providing guidance and support to customers for the discovery and development of novel medicines. We have grown significantly…
